GENE ONLINE|News &
Opinion
Blog

2022-07-14| R&D

New Mitochondrial Response Pathway May Advance Treatments for Inflammatory Diseases

by Fujie Tham
Share To

In a study published on Immunity, University of California San Diego researchers described the biochemical pathway that results in the generation of oxidized mtDNA, how mitochondria expel it and cause the powerful and catastrophic inflammatory response observed in autoimmune conditions like lupus and rheumatoid arthritis.

Each mitochondrion contains copies of mitochondrial DNA (mtDNA). In response to cell damage or stress, mtDNA is expelled from the mitochondrion, oxidized, cleaved, and then triggers immune and inflammatory responses. mtDNA release into the cytosol or bloodstream can occur as a response to sepsis, traumatic injury, or cytotoxicity. While the concentration of circulating oxidized mtDNA in the bloodstream corresponds with the severity of autoimmune conditions, scientists are still unsure if mtDNA is simply a biomarker or if it plays a significant role in disease pathology.

Related article: TALED Tool Launches a New Era of Mitochondrial Genome Editing

 

Critical Role of FEN1 in Fueling the “Auto-Inflammatory Fire”

 

The researchers discovered that when macrophages come in contact with metabolic stress/danger signals, the mitochondria reacted to take up calcium ions from the cytosol, resulting in the generation and release of oxidized mtDNA (Ox-mtDNA) through the opening of mitochondrial permeability transition pores.

However, oxidized mitochondrial DNA is large, making it unlikely to escape via the pores on the mitochondrial membrane. The team identified that endonuclease FEN1 is responsible for cleaving large mtDNA into smaller segments, allowing escape and leading to further inflammatory activations. These smaller mtDNA fragments then go on to activate NLRP3 and cGAS, NLRP3 is part of a multi-protein complex called the inflammasome that activates inflammatory responses, while cGAS is an enzyme that generates a small molecule that acts as a chemical messenger to encourage the production of other cytokines. Overexcitation of both NLRP3 and cGAS is characteristic in patients with autoimmune diseases, where the immune system attacks normal body tissues.

These new findings shed light on how mitochondria affect the immune system with the pathway, FEN1’s role in triggering the immune cascade, and how possible therapeutic interventions may be developed for autoimmune diseases such as lupus and arthritis.

 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
Netherlands-based Argenx Raises $1.1 Billion in Global Offering Following Success in Clinical Trials
2023-07-23
M&A
Merck Buys Prometheus For $10.8 Billion, Lands Promising Autoimmune Asset
2023-04-17
Vera Therapeutics Eyes Phase 3 For Kidney Disease Candidate Following Positive Data
2023-01-04
LATEST
Mechanisms of Allograft Rejection: Insights from Behind the Scenes
2024-04-25
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
Takeda, Astellas, and Sumitomo Mitsui Banking Declare Agreement For Early Drug Discovery Program Incubation in Joint Venture
2024-04-23
Ochre Bio Announces Partnership with Boehringer Ingelheim to Develop Novel Regenerative Treatments for Patients with Advanced Liver Disease
2024-04-22
Earth Day Awareness: Hospitals Embrace Sustainability Efforts
2024-04-22
WHO Raises Alarm: Bird Flu Threat to Humans an ‘Enormous Concern’
2024-04-19
The Legal Battlefield of Weight-Loss Drugs: Eli Lilly and Novo Nordisk on the Defensive
2024-04-18
EVENT
2024-04-27
2024 Biomedical Final Pitch Competition
Room DA1620, Dana Building, Dana-Farber Cancer Institute, 99 Jimmy Fund Way, Boston, MA 02115
Scroll to Top